Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 531 to 540 of 2440 total matches.
Prucalopride (Motegrity) for Chronic Idiopathic Constipation
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
of anal blockage
or incomplete evacuation, and a need for manual
maneuvers to aid defecation.1 ...
The FDA has approved the 5-HT4 receptor agonist
prucalopride (Motegrity – Shire) for treatment of chronic
idiopathic constipation (CIC) in adults. Prucalopride is
the only drug currently approved in the US for treatment
of CIC that stimulates colonic peristalsis. It has been
available in Europe and Canada for several years.
Risankizumab (Skyrizi) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
.
The first year of treatment costs $88,500.
Its long-term safety is unknown.
Table 1. Pharmacology
Class ...
The FDA has approved the interleukin (IL)-23
antagonist risankizumab-rzaa (Skyrizi – Abbvie) for
treatment of moderate to severe plaque psoriasis in
adults. Risankizumab is the third IL-23 antagonist to
be approved for this indication; guselkumab (Tremfya)
and tildrakizumab (Ilumya) were approved earlier.
Expanded Table: Some Drugs for Chronic Idiopathic Constipation (online only)
The Medical Letter on Drugs and Therapeutics • Jun 03, 2019 (Issue 1573)
, mean spontaneous bowel
movement frequency in week
1 was 5.7-5.9 with the drug and
3.5-4.0 ...
View the Expanded Table: Some Drugs for Chronic Idiopathic Constipation
PrabotulinumtoxinA (Jeuveau) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota ...
The FDA has approved prabotulinumtoxinA-xvfs
(Jeuveau – Evolus) for temporary improvement in
the appearance of moderate to severe glabellar lines
associated with corrugator and/or procerus muscle
activity. Jeuveau is the fourth botulinum toxin
product to be approved in the US for this indication
(see Table 1). It has been available in South Korea as
Nabota since 2014.
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
to
tetracyclines.
Pronunciation Key
Omadacycline: oh mad" a sye' kleen Nuzyra: new zye' rah
Table 1 ...
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Inhaled Levodopa (Inbrija) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-B) inhibitor.1
Levodopa is absorbed in the proximal small intestine.
In patients with advanced PD ...
The FDA has approved Inbrija (Acorda), an orally
inhaled dry-powder formulation of levodopa, for
intermittent treatment of "off" episodes in patients
with Parkinson's disease (PD) being treated with
carbidopa/levodopa (Sinemet, and others).
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-linked
recessive deficiency of coagulation factor VIII that
occurs in about 1 in 5000 male births ...
The FDA has approved emicizumab-kxwh (Hemlibra –
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.
Insulins for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
patients, the target A1C is ...
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
Brexanolone (Zulresso) for Postpartum Depression
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
for treatment of refractory PPD.1
PHARMACOLOGY — Brexanolone positively modulates
neuronal activation ...
The FDA has approved the GABAA receptor modulator
brexanolone (Zulresso – Sage Therapeutics) for
IV treatment of postpartum depression (PPD).
Brexanolone is the first drug to be approved by the FDA
for this indication.
Siponimod (Mayzent) - A New Drug for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • May 06, 2019 (Issue 1571)
–
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing ...
The FDA has approved siponimod (Mayzent –
Novartis), a sphingosine 1-phosphate (S1P) receptor
modulator, for oral treatment of adults with relapsing
forms of multiple sclerosis (MS), including clinically
isolated syndrome (initial neurological episode),
relapsing-remitting disease, and active secondary
progressive MS (SPMS). Siponimod is the second
S1P receptor modulator to be approved in the US;
fingolimod (Gilenya), which is approved for oral
treatment of relapsing forms of MS in patients ≥10
years old, was the first. The purine antimetabolite
cladribine (Mavenclad) was also...